You are here
Biodesix Test Predicts Response to Atezolizumab in Lung Cancer
Researchers Present New Data from Blood-Based Proteomic Test in Biomarkers and Immune Monitoring at SITC 2018
BOULDER, Colo. and WASHINGTON, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Researchers with Biodesix® and Genentech, a member of the Roche Group, today presented findings on a test designed to predict response to atezolizumab (Tecentriq®) in patients with non-small cell lung cancer (NSCLC). The blood-based test, which uses expression data from the circulating proteome to classify patients, was found to be predictive for OS and PFS between atezolizumab and docetaxel. These data suggest a patient’s likelihood of benefiting from PD-L1 checkpoint inhibition can be identified through circulating proteome in blood samples. Researchers presented their findings at the Society for Immunotherapy of Cancer (SITC) annual meeting in Washington, D.C.
“Immunotherapy has become a standard of care in NSCLC and it is important to better understand the mechanisms of efficacy and resistance in patients,” said Heinrich Roder, D. Phil and CTO of Biodesix. “This study demonstrated the effectiveness of monitoring the proteome to identify patients who will receive optimal benefits from anti-PD-L1 therapy.”
The abstract presented at SITC 2018 can be found here.
Biodesix is a lung cancer diagnostic company addressing the continuum of patient care from early diagnosis of lung nodules through late stage cancer. The company develops diagnostic tests addressing important clinical questions by combining simple blood draws and multi-omics with the power of artificial intelligence. Biodesix is the first company to offer three best-in class tests for patients with non-small cell lung cancer, and multiple pipeline tests including one with the potential to identify patients who may benefit from immunotherapies. The Biodesix Lung Reflex strategy integrates the GeneStrat® and VeriStrat® tests to support treatment decisions with results in 72 hours. The BDX-XL2 nodule test evaluates the risk of malignancy, enabling physicians to triage patients to the most appropriate course of action. Biodesix also partners with the world’s leading biotechnology and pharmaceutical companies to develop companion diagnostics. For more information about Biodesix, please visit www.biodesix.com.
Tecentriq® (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.
Kena Hudson for Biodesix